Gujarat Terce Laboratories Quarterly Results
Gujarat Terce Laboratories quarterly results. In Sept 2021, Gujarat Terce Laboratories (GUJTERC) reported revenue ₹10 Cr and net profit ₹0 Cr — revenue +42.9% YoY. Check GUJTERC market cap trends to track the company's total market size over time.
GUJTERC Quarterly Results — Revenue, Profit & EPS Highlights
Gujarat Terce Laboratories latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Gujarat Terce Laboratories screener.
- Revenue of ₹10 Cr in Sept 2021 (+0.0% vs Jun 2021, +42.9% vs Sept 2020)
- EBITDA of ₹1 Cr in Sept 2021 (-50.0% vs Jun 2021)
- Operating Margin of 5.0% in Sept 2021 (-11.0pp vs Jun 2021)
- Earnings Per Share of ₹0.61 in Sept 2021 (-71.8% vs Jun 2021)
Gujarat Terce Laboratories Quarterly Results — Revenue, EBITDA, Net Profit & EPS
GUJTERC quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2021 | Jun 2021 | Sept 2020 | Mar 2020 | Jun 2020 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 10 | 10 | 7 | 10 | 5 | - | 42.9% |
| Net Profit (₹ Cr) | 0 | 2 | 0 | -1 | 0 | - | - |
| EBITDA (₹ Cr) | 1 | 2 | 0 | 0 | 0 | - | - |
| EPS (₹) | 0.61 | 2.16 | -0.02 | 0.00 | -0.60 | - | - |
| Operating Margin (%) | 5.0% | 16.0% | 2.0% | -5.0% | -8.0% | - | - |
GUJTERC Share Price Trend — 1-Year Movement Across Quarterly Results
Gujarat Terce Laboratories 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Review GUJTERC earnings multiple to evaluate earnings-based valuation against sector peers.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
GUJTERC vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Gujarat Terce Laboratories latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Laurus Labs
Mar 2026 |
₹109,629.35 Cr | 1971.4 | 1,823 | 282 | -10.5% | - | 15.5% | 381.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores